prikaz prve stranice dokumenta Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer
Rad nije dostupan
Znanstveni rad - Pregledni rad
Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer
Trends in Cancer, 7 (2021), 1; 57-76. https://doi.org/10.1016/j.trecan.2020.08.003
Bursać, Slađana; Prodan, Ylenia; Pullen, Nick; Bartek, Jiri; Volarević, Siniša

Citirajte ovaj rad

Bursać, S., Prodan, Y., Pullen, N., Bartek, J. i Volarević, S. (2021). Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer. Trends in Cancer, 7. (1), 57-76. doi: 10.1016/j.trecan.2020.08.003

Bursać, Slađana, et al. "Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer." Trends in Cancer, vol. 7, br. 1, 2021, str. 57-76. https://doi.org/10.1016/j.trecan.2020.08.003

Bursać, Slađana, Ylenia Prodan, Nick Pullen, Jiri Bartek i Siniša Volarević. "Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer." Trends in Cancer 7, br. 1 (2021): 57-76. https://doi.org/10.1016/j.trecan.2020.08.003

Bursać, S., et al. (2021) 'Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer', Trends in Cancer, 7(1), str. 57-76. doi: 10.1016/j.trecan.2020.08.003

Bursać S, Prodan Y, Pullen N, Bartek J, Volarević S. Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer. Trends in Cancer [Internet]. 2021. [pristupljeno 16.02.2025.];7(1):57-76. doi: 10.1016/j.trecan.2020.08.003

S. Bursać, Y. Prodan, N. Pullen, J. Bartek i S. Volarević, "Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer", Trends in Cancer, vol. 7, br. 1, str. 57-76, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:723535. [Citirano: 16.02.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:723535
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer
AutorSlađana Bursać
AutorYlenia Prodan
AutorNick Pullen
AutorJiri Bartek
AutorSiniša Volarević
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za molekularnu medicinu i biotehnologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Genetika, genomika i proteomika čovjeka
Znanstveno / umjetničko
područje, polje i grana		BIOTEHNIČKE ZNANOSTI
Biotehnologija
Sažetak (engleski)
Ribosome biogenesis (RiBi) is one of the most complex and energy demandingprocesses in human cells, critical for cell growth and proliferation. Strong causallinks between inherited and acquired impairment in RiBi with cancer pathogene-sis are emerging, pointing to RiBi as an attractive therapeutic target for cancer.Here, we will highlight new knowledge about causes of excessive or impairedRiBi and the impact of these changes on protein synthesis. We will also discusshow new knowledge about secondary consequences of dysregulated RiBi andprotein synthesis, including proteotoxic stress, metabolic alterations, adaptivetranscriptional and translational programs, and the impaired ribosome biogenesischeckpoint (IRBC) provide a foundation for the development of new anticancertherapies
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaTrends in Cancer
Brojčani podacivol. 7, br. 1, str. 57-76
p-ISSN2405-8033
DOIhttps://doi.org/10.1016/j.trecan.2020.08.003
URN:NBNurn:nbn:hr:184:723535
Datum objave publikacije2021
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S2405803320302351
Vrsta resursaTekst
Prava pristupaZatvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2020-09-24 07:24:44